177 related articles for article (PubMed ID: 35069595)
21. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
Romano A; Parrinello NL; La Cava P; Tibullo D; Giallongo C; Camiolo G; Puglisi F; Parisi M; Pirosa MC; Martino E; Conticello C; Palumbo GA; Di Raimondo F
Expert Rev Mol Diagn; 2018 Jul; 18(7):675-683. PubMed ID: 29707981
[TBL] [Abstract][Full Text] [Related]
22. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
[TBL] [Abstract][Full Text] [Related]
23. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
24. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.
Rodrigues JC; Gonzalez GC; Zhang L; Ibrahim G; Kelly JJ; Gustafson MP; Lin Y; Dietz AB; Forsyth PA; Yong VW; Parney IF
Neuro Oncol; 2010 Apr; 12(4):351-65. PubMed ID: 20308313
[TBL] [Abstract][Full Text] [Related]
25. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
Christiansson L; Söderlund S; Svensson E; Mustjoki S; Bengtsson M; Simonsson B; Olsson-Strömberg U; Loskog AS
PLoS One; 2013; 8(1):e55818. PubMed ID: 23383287
[TBL] [Abstract][Full Text] [Related]
26. CD14
Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
[TBL] [Abstract][Full Text] [Related]
27. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.
Kohanbash G; McKaveney K; Sakaki M; Ueda R; Mintz AH; Amankulor N; Fujita M; Ohlfest JR; Okada H
Cancer Res; 2013 Nov; 73(21):6413-23. PubMed ID: 24030977
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
29. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
30. Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis.
Uhel F; Azzaoui I; Grégoire M; Pangault C; Dulong J; Tadié JM; Gacouin A; Camus C; Cynober L; Fest T; Le Tulzo Y; Roussel M; Tarte K
Am J Respir Crit Care Med; 2017 Aug; 196(3):315-327. PubMed ID: 28146645
[TBL] [Abstract][Full Text] [Related]
31. Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer.
Jiao ZJ; Gao JJ; Hua SH; Chen DY; Wang WH; Wang H; Wang XH; Xu HX
World J Gastroenterol; 2012 Oct; 18(38):5454-61. PubMed ID: 23082063
[TBL] [Abstract][Full Text] [Related]
32. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Hoechst B; Ormandy LA; Ballmaier M; Lehner F; Krüger C; Manns MP; Greten TF; Korangy F
Gastroenterology; 2008 Jul; 135(1):234-43. PubMed ID: 18485901
[TBL] [Abstract][Full Text] [Related]
33. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
34. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
[TBL] [Abstract][Full Text] [Related]
35. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
36. Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus.
Park MJ; Baek JA; Choi JW; Jang SG; Kim DS; Park SH; Cho ML; Kwok SK
Front Immunol; 2021; 12():606024. PubMed ID: 33986739
[TBL] [Abstract][Full Text] [Related]
37. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
Front Immunol; 2020; 11():1299. PubMed ID: 32719675
[No Abstract] [Full Text] [Related]
38. Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.
Jacobs DI; Liu Y; Gabrusiewicz K; Tsavachidis S; Armstrong GN; Zhou R; Wei J; Ivan C; Calin G; Molinaro AM; Rice T; Bracci PM; Hansen HM; Wiencke JK; Wrensch MR; Heimberger AB; Bondy ML
J Neurooncol; 2018 Jan; 136(1):33-39. PubMed ID: 28965162
[TBL] [Abstract][Full Text] [Related]
39. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
40. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]